=== SUMMARY ===
- Author analyzes BBW after a ~30% drop, acknowledging shrinking revenue but pointing to a clean balance sheet and normalized FCF.
- Uses a basic DCF with $35M normalized FCF, 2-3% growth, 10.5% discount rate, and $14M cash/no debt to estimate fair value at ~$37/share.
- Overall tone is cautiously constructive: valuation looks more interesting after the selloff, though not a screaming buy.
Quality assessment: Rough DCF-based speculation rather than deep fundamental DD; the thesis depends heavily on normalized FCF assumptions and limited discussion of why revenue is shrinking.
=== SENTIMENT ===
MIXED
=== TRADE IDEAS ===
BBW - LONG | confidence: 0.55 | sentiment: +0.3
Speaker: u/Sufficient-Flan1565
Thesis:
1. THE FACT: Author estimates ~$35M normalized FCF, ~$14M cash, essentially no debt, and DCF fair value around $37/share vs. ~$25 bear case.
2. THE BRIDGE: After the ~30% selloff, the market may be over-weighting revenue shrinkage while ignoring the balance sheet and normalized cash generation.
3. THE VERDICT: Potential value opportunity for a patient long, but confidence is tempered by revenue decline and DCF sensitivity.
4. RISKS: Continued revenue contraction, weaker FCF than normalized, higher discount rate justified, or further retail sector weakness.
Timeframe: medium-term
Key Points:
- Valuation more interesting after ~30% drop
- DCF fair value ~$37/share
- Bear case ~$25/share
- Revenue decline is key unknown
- Clean balance sheet with no debt
Оценка15
Комментарии35
% апвоутов89%
▶ Полный текст поста
Folks,
What are we thinkin about BBW after today's \~30% drop? Revenue is shrinking, I get that.
However, using roughly $35M normalized annual FCF as a starting point, I ran a pretty basic DCF with ChatGPT with these assumptions: 3% FCF growth for years 1–5, 2% growth years 6–10, 2% terminal growth, 10.5% discount rate, and \~$14M cash/essentially no debt.
Getting fair value around **$37/share**. Bear case assuming weaker \~$32M FCF, minimal growth and a 12% discount rate gives me roughly $25/share.
Not saying it’s a screaming buy, but the valuation looks much more interesting after today’s selloff.
Author estimates ~$35M normalized FCF, ~$14M cash, essentially no debt, and DCF fair value around $37/share vs. ~$25 bear case. After the ~30% selloff, the market may be over-weighting revenue shrinkage while ignoring the balance sheet and normalized cash generation. Potential value opportunity for a patient long, but confidence is tempered by revenue decline and DCF sensitivity. Continued revenue contraction, weaker FCF than normalized, higher discount rate justified, or further retail sector weakness.
This Reddit post, published August 28, 2026,
features u/Sufficient-Flan1565
discussing BBW.
1 trade idea extracted by AI with direction and confidence scoring.